DIA Opens New Office in China
DIA, the multidisciplinary, non-profit association that provides a neutral forum for the exchange of information critical to the advancement of the drug discovery and life cycle management processes, has opened an office in Beijing, China.
DRUG INFORMATION ASSOCIATION (DIA) OPENS NEW OFFICE IN CHINA
BEIJING, CHINA—NOVEMBER 18, 2008—The Drug Information Association (DIA) <http://www.diahome.org/> , the premier, multidisciplinary, non-profit association that provides a neutral forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes, has opened an office in Beijing, China.
“China's pharmaceutical industry has become a major force in drug discovery and development,” explains William Brassington, Acting DIA Worldwide Executive Director. “As the premier provider of neutral global forums for the exchange of information, education, and training, it is imperative that we solidify our presence in the region.”
DIA’s regional office in China adds another dimension to DIA’s worldwide operations. DIA’s headquarters in Horsham, PA (USA) is supported by regional offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India.
“DIA’s success in China depends on our ability to engage local thought leaders in DIA’s unique educational and networking events, where they will be able to exchange professional experiences,” says Marie Dray, President, DIA Board of Directors.
The Provisional Advisory Council of China (pACC) was established in May 2008 and will continue to provide support and strategic oversight for DIA’s presence in China. The pACC will focus on developing a strong membership and volunteer base, strategic alliances, conferences and training programs, and local and student chapters. DIA Board Member Ling Su, PhD, Vice President, Clinical Research & Development - Asia Pacific, Wyeth, China, is pACC chair.
“An influx of western-trained scientists and increased access to global markets are extending the development opportunities available in China,” says Ling Su. “DIA's presence in China will certainly contribute to meeting the enormous needs in training, education, and information sharing and exchange in global drug development and access to new medicines. DIA will follow the same successful formula used in North America, Europe, Japan, and India while working collaboratively with the SFDA, the China-based pharmaceutical industry, CROs, research institutions and other stakeholders.”
In China, DIA has partnered with the Kellen Company to provide management and logistical support. With offices in the U.S., Europe, and China, Kellen offers a complete range of services to international, national and regional associations, professional societies, foundations, and businesses. Kellen will provide:
- Full office outsourced management of DIA in China
- Management and logistical support for pACC activities
- Conference and training course organization and support
- Membership development and recruitment
"DIA is confident that Dr. Ling Su, with the support of an outstanding headquarters team and an experienced local agency, will lead DIA’s volunteer advisory council in China in an effort to expand our capabilities in the region," explains Dray.
About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA (USA), and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org <http://www.diahome.org/> or call 215-442-6100.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
